Click here to read the Cover Story, "Emerging treatments bring hope for patients for geographic atrophy."
Dealing with new-onset macular exudation while treating geographic atrophy with the complement inhibitors currently undergoing investigation seems a risk not worth the reward.
Based on the best available data we have from Apellis, the treatment effect of APL-2 (pegcetacoplan) is not profound. We have an average of less than a 20% reduction in geographic atrophy (GA) lesion growth as a primary endpoint when the data from both trials are pooled. This means that we would be treating